NASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis $4.81 -0.18 (-3.61%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.87 +0.06 (+1.25%) As of 08/1/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aldeyra Therapeutics Stock (NASDAQ:ALDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aldeyra Therapeutics alerts:Sign Up Key Stats Today's Range$4.23▼$4.9250-Day Range$2.12▼$5.5352-Week Range$1.14▼$7.20Volume1.51 million shsAverage Volume1.16 million shsMarket Capitalization$288.10 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingBuy Company Overview Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. Read More Aldeyra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreALDX MarketRank™: Aldeyra Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 796th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aldeyra Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Aldeyra Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.73% of the outstanding shares of Aldeyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 3.58%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.73% of the outstanding shares of Aldeyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 3.58%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Aldeyra Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows2 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aldeyra Therapeutics' insider trading history. Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALDX Stock News HeadlinesAldeyra says FDA accepted resubmitted marketing application for lead drugJuly 17, 2025 | msn.comAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseJuly 17, 2025 | businesswire.comHoward Hughes greatest discoveryIn 1974, the CIA used a fake mining operation to recover a Soviet nuclear sub—and accidentally uncovered something far more valuable: strange rocks on the ocean floor packed with critical metals. Today, those same metals are essential to AI, EVs, quantum computing, and defense. And thanks to recent action from the Trump administration, a $16 trillion treasure could finally be tapped—with one tiny U.S. company at the center of it all.August 2 at 2:00 AM | Porter & Company (Ad)Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?July 15, 2025 | msn.comAldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber DataJuly 2, 2025 | seekingalpha.comAldeyra stock jumps after FDA agreement on cancer drug trial designJune 26, 2025 | au.investing.comAldeyra Shares Climb on FDA Backing for PVRL Drug Trial DesignJune 26, 2025 | msn.comAldeyra resubmits Reproxalap's marketing application to FDAJune 18, 2025 | msn.comSee More Headlines ALDX Stock Analysis - Frequently Asked Questions How have ALDX shares performed this year? Aldeyra Therapeutics' stock was trading at $4.99 at the beginning of the year. Since then, ALDX shares have decreased by 3.6% and is now trading at $4.81. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) issued its quarterly earnings data on Wednesday, May, 14th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08. Who are Aldeyra Therapeutics' major shareholders? Top institutional shareholders of Aldeyra Therapeutics include Woodstock Corp (0.45%), PFG Investments LLC (0.43%), CWM LLC (0.07%) and Ballast Inc. (0.05%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Bruce Greenberg and Nancy Miller-Rich. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings5/14/2025Today8/02/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALDX CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees10Year FoundedN/APrice Target and Rating Average Price Target for Aldeyra Therapeutics$9.50 High Price Target$10.00 Low Price Target$9.00 Potential Upside/Downside+97.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-72.58% Return on Assets-52.32% Debt Debt-to-Equity Ratio0.24 Current Ratio6.49 Quick Ratio6.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book4.04Miscellaneous Outstanding Shares59,896,000Free Float54,146,000Market Cap$288.10 million OptionableOptionable Beta0.90 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ALDX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.